Immune checkpoint inhibitors have significantly transformed the treatment paradigm for
metastatic renal cell carcinoma (RCC), offering prolonged overall survival and achieving …

The incidence of renal cell carcinoma (RCC) is increasing worldwide, yet research within
this field is lagging behind other cancers. Despite increased detection of early disease as a …

Background Further stratification of the risk of recurrence of clear-cell renal cell carcinoma
(ccRCC) with venous tumor thrombus (VTT) will facilitate selection of candidates for adjuvant …

Background Clear cell renal cell carcinoma (ccRCC) is the most common subtype of RCC,
and accurate grading is crucial for prognosis and treatment selection. Biopsy is the …

In this review, we highlight and contextualize emerging morphologic prognostic and
predictive factors in renal cell carcinoma. We focus on clear cell renal cell carcinoma …

Background Metastatic RCC with sarcomatoid and/or rhabdoid (S/R) dedifferentiation is an
aggressive disease associated with improved response to immune checkpoint therapy (ICT) …

Most patients diagnosed with clear cell renal cell carcinoma (ccRCC) are also detected with
small and organ‐confined tumors, and the majority of these are classified as clinical tumor …

Objective To evaluate post‐nephrectomy outcomes and predictors of cancer‐specific
survival (CSS) between patients with localised sarcomatoid renal cell carcinoma (sRCC) …

Background Considering the reported greater benefits of immunotherapy and its
unignorable adverse events in adjuvant therapy for high-risk renal cell carcinoma (hrRCC) …

Sarcomatoid dedifferentiation is common to multiple renal cell carcinoma (RCC) subtypes,
including chromophobe RCC (ChRCC), and is associated with increased aggressiveness …